Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DEAH-box helicase 40 is a member of the DExH/D box family of ATP-dependent RNA helicases, essential for RNA metabolism, especially in processes such as RNA duplex unwinding, pre-mRNA splicing, regulation of non-coding RNAs, and ribosome biogenesis[2][3]. It is implicated as a candidate susceptibility gene for cancer, with functional loss associated with hematological and solid malignancies[2][3]. DHX40 functions by hydrolyzing ATP and facilitating RNA conformational changes required for cellular RNA processing. It possesses multiple functional domains: a DEAD/H box helicase domain, a conserved C-terminal domain, and an HA2 (helicase-associated) domain. Alterations in DHX40 affect splicing events and may result in aberrant RNA metabolism, contributing to disease pathology, especially in cancer[2][3].
Not directly targeted by drugs, but inhibition or modulation of DHX40 may disrupt RNA metabolism, splicing, and translation, which are attractive areas for anti-cancer therapy development
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DEAH-box helicase 40 (DHX40).